For a generation of young women, a breast cancer diagnosis has carried a silent second sentence: the children you hoped for may not be possible. The POSITIVE trial, now followed for nearly six years, has quietly rewritten that sentence. Conducted across international sites and led by researchers at Dana-Farber Cancer Institute, the study demonstrates that premenopausal women with hormone receptor–positive breast cancer can pause endocrine therapy to conceive, carry, and deliver children without measurable worsening of their cancer outcomes — replacing decades of cautious default with prospecti
The ASCO Post
· Apr 13, 2026
· health
· 6 min de leitura
High
Apuração: Verificado
POSITIVE Trial: Pausing Endocrine Therapy for Pregnancy Does Not Worsen Breast Cancer Outcomes at 5 Years
Young women with breast cancer previously faced a 5–10 year fertility delay due to endocrine therapy requirements, causing significant psychological and reproductive burden.
◉
Health & Medicine
7994 artigos relacionados
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% correspondência
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% correspondência
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Viés e Enquadramento
⚖
Medical trade publication presents clinical trial results with advocacy framing, centering patient empowerment narrative alongside scientific findings.
Bias Direction
center-left
Confidence
MED
Patient empowerment and quality-of-life framing used to contextualize clinical data, emphasizing reassurance and positive outcomes while minimizing uncertainty or risk discussion.
ball and chain
life-altering
clinical conundrum
formidable obstacle
reassuring evidence
carefully managed
indeed positive and reassuring
Oncologists or researchers with cautionary views on pausing endocrine therapy
Patients who experienced adverse outcomes during treatment interruption
Statistical context for the 24% who did not achieve live births
Long-term recurrence risk data beyond 71 months
Perspectives from patients who chose not to pause therapy
Health economists on cost-benefit of extended monitoring during pause
Impacto Geopolítico
🌎
Medical trial on breast cancer treatment has no meaningful geopolitical implications; this is a clinical oncology finding with no international security or power dimensions.
Escalation Risk
low
Confidence
HIGH
No shifts in power, alliances, or geopolitical influence are associated with this medical research publication. It is a clinical trial result from an international oncology consortium.
Lente Econômica
📈
POSITIVE trial confirms safe endocrine therapy pause for pregnancy in HR+ breast cancer, expanding treatment options and potentially boosting fertility/oncology markets.
Market Signal
bullish
Confidence
MED
Pharmaceuticals & Oncology
Fertility & Reproductive Medicine
Health Insurance & Managed Care
Women's Healthcare
Medical Research & Clinical Trials
Hospital & Outpatient Oncology Services
Young premenopausal breast cancer patients gain validated clinical pathway to pursue pregnancy without forgoing cancer treatment, reducing psychological and financial burden of choosing between family planning and survival. May reduce long-term costs associated with prolonged endocrine therapy interruptions managed without guidance.
Insurers and health systems may need to update coverage guidelines for fertility preservation and treatment interruption protocols. Oncology clinical guidelines (NCCN, ASCO) likely to be revised. Potential regulatory interest in labeling updates for endocrine therapy drugs. Could drive increased funding for reproductive oncology programs and workforce expansion.